Nektar Therapeutics · NASDAQ:NKTR
Zalevsky Jonathan sold 192 Nektar Therapeutics shares (Form 4)
Traded Nov 17, 2026 · Filed Nov 19, 2026
On Nov 17, 2026, Zalevsky Jonathan (Chief R&D Officer) sold 192 Nektar Therapeutics shares at US$35.85 for US$6,883, leaving 9,378 shares. Filed Nov 19, 2026 (Form 4).
- Sold
- 192 shares
- Price
- US$35.85
- Value
- US$6,883
- Holding after
- 9,378 shares
- Trading plan
- No
- Role
- Chief R&D Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Common Stock | Sale | 192 | US$35.85 | 9,378 | Direct |
Source
Download original · View original at SEC
Related
- Nektar Therapeutics
- Zalevsky Jonathan
- Nektar Therapeutics shareholders
- Form 4 · Zalevsky Jonathan · Aug 20, 2026
- Form 4 · Zalevsky Jonathan · Jul 2, 2026
- Form 4 · Zalevsky Jonathan · Jun 17, 2026
- Form 4 · Zalevsky Jonathan · May 21, 2026
- Form 4 · Robin Howard W · Nov 19, 2026
- Schedule 13G · State Street Corp · Nov 10, 2026
- Schedule 13G/A · Two Seas Capital LP · Sep 28, 2026
- Form 4 · Whitfield Roy A · Sep 25, 2026
- Form 4 · Greer R Scott · Sep 25, 2026